Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 11:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 815 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Recurrent Lung Carcinoma Clear all
Completed Phase 1Phase 2 Interventional Results available

Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer

NCT00096486
View directory record Official record
Conditions
Lung Cancer
Interventions
everolimus, gefitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 6, 2026, 11:17 AM EDT
Completed Phase 2 Interventional

Capecitabine in Treating Patients With Malignant Mesothelioma

NCT00004183
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
capecitabine
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
50
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 6, 2026, 11:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer

NCT00093756
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
3-dimensional conformal radiation therapy, bortezomib, paclitaxel, carboplatin
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
143
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 6, 2026, 11:17 AM EDT
Completed Phase 1 Interventional

131-I-TM-601 Study in Adults With Solid Tumors

NCT00379132
View directory record Official record
Conditions
Breast Cancer, Non-Small Cell Lung Cancer, Melanoma, Colorectal Cancer, Pancreatic Cancer, Prostate Adenocarcinoma, Glioma, Primary Solid Tumors
Interventions
131-I-TM-601 (chlorotoxin)
Drug
Lead sponsor
TransMolecular
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2009 · Synced Oct 6, 2026, 11:17 AM EDT
Terminated Phase 1 Interventional

An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

NCT04189614
View directory record Official record
Conditions
Cancer, Non-small Cell Lung Cancer (NSCLC)
Interventions
Cofetuzumab Pelidotin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
12
States / cities
Birmingham, Alabama • Springdale, Arkansas • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 6, 2026, 11:17 AM EDT
Active, not recruiting Phase 2 Interventional

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

NCT03410043
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Osimertinib, Radiation Therapy, Therapeutic Conventional Surgery
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
San Francisco, California • Denver, Colorado • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 6, 2026, 11:17 AM EDT
Completed Phase 2 Interventional Results available

An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

NCT03001882
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
Springdale, Arkansas • New Haven, Connecticut • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 6, 2026, 11:17 AM EDT
Completed Phase 1 Interventional

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT02947386
View directory record Official record
Conditions
EGFR Gene Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Laboratory Biomarker Analysis, Nimotuzumab, Nivolumab
Other · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 6, 2026, 11:17 AM EDT
Not listed Phase 2Phase 3 Interventional

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

NCT00030641
View directory record Official record
Conditions
Lung Cancer
Interventions
oblimersen sodium, docetaxel
Biological · Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
35
States / cities
Birmingham, Alabama • Montgomery, Alabama • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 6, 2026, 11:17 AM EDT
Terminated Phase 2 Interventional Results available

Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

NCT00955305
View directory record Official record
Conditions
Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer, Bronchioloalveolar Lung Carcinoma
Interventions
Bevacizumab, Carboplatin, Cixutumumab, Paclitaxel
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
165
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 122 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 6, 2026, 11:17 AM EDT
Not yet recruiting Phase 2 Interventional

Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer

NCT07793253
View directory record Official record
Conditions
Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma, Ampulla of Vater Carcinoma, Ampullary Carcinoma
Interventions
Daraxonrasib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 6, 2026, 11:17 AM EDT
Completed Phase 1 Interventional

All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

NCT04919369
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Atezolizumab, Tretinoin
Biological · Drug
Lead sponsor
Dwight Owen
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 6, 2026, 11:17 AM EDT
Completed Phase 2 Interventional

Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

NCT00010218
View directory record Official record
Conditions
Lung Cancer
Interventions
karenitecin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
44
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 6, 2026, 11:17 AM EDT
Completed Phase 3 Interventional Results available

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

NCT00377156
View directory record Official record
Conditions
Breast Cancer, Cognitive/Functional Effects, Lung Cancer, Metastatic Cancer, Prostate Cancer
Interventions
radiation therapy, stereotactic radiosurgery
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
60
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Modesto, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 6, 2026, 11:17 AM EDT
Completed Phase 2 Interventional Results available

Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence

NCT00915005
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Photon Therapy, Proton Therapy, Paclitaxel, Carboplatin
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 6, 2026, 11:17 AM EDT
Completed Phase 1 Interventional

Interleukin-12 in Treating Patients With Cancer in the Abdomen

NCT00003046
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
Recombinant Interleukin-12
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 6, 2026, 11:17 AM EDT
Completed Phase 2 Interventional Results available

Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer

NCT00284154
View directory record Official record
Conditions
Carcinoma, Small Cell, Lung Cancer
Interventions
Vinflunine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Fort Myers, Florida • Cincinnati, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Oct 6, 2026, 11:17 AM EDT
Completed Phase 1 Interventional

Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

NCT00622674
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cetuximab, bortezomib
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 6, 2026, 11:17 AM EDT
Completed Phase 2 Interventional Results available

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

NCT00309946
View directory record Official record
Conditions
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
Interventions
cediranib maleate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 6, 2026, 11:17 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pembrolizumab + Idelalisib for Lung Cancer Study

NCT03257722
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Metastasis, Recurrence
Interventions
Pembrolizumab, Idelalisib
Drug
Lead sponsor
Asha Nayak
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 6, 2026, 11:17 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

NCT00019331
View directory record Official record
Conditions
Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma (Skin), Pancreatic Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, ras peptide cancer vaccine, sargramostim, DetoxPC
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 6, 2026, 11:17 AM EDT
Completed Phase 1 Interventional

Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer

NCT01837329
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Tetrathiomolybdate
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 6, 2026, 11:17 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00118131
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, docetaxel
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
13
States / cities
East Brunswick, New Jersey • Edison, New Jersey • Freehold, New Jersey + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 6, 2026, 11:17 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer

NCT00728845
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, hydroxychloroquine, paclitaxel
Biological · Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Hamilton, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 6, 2026, 11:17 AM EDT